Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 15

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 15
---
824 shares and had an exercise price of $22.72 per share. As
consideration for the

9

Exercise, we agreed to (A) reduce the exercise price of the foregoing warrants exercised by the Exercising Investor to $22.51 per share and (B) issue to the Exercising Investor the November 2025
Investor Warrant. The closing for the Warrant Inducement Agreement occurred on November 25, 2025.

In connection with the Exercise,
we issued to StockBlock and its affiliate, Rodman & Renshaw LLC or their respective designees, the November 2025 Placement Agent Warrants. The November 2025 Placement Agent Warrants have the same terms as the November 2025 Investor Warrant
described above.

The Company

We are
an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high
unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes.

Our commercial products are: (i) ZTlido (lidocaine topical system) 1.8%, a
prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia (“PHN”), which is a form of post-shingles nerve
pain; (ii) ELYXYB, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and
(iii) GLOPERBA, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults, which launched in June 2024.
In addition, we have three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SP-102” or “SEMDEXA”), a
novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica for which we initiated a second Phase 3 study in September 2025; (ii)
SP-103 (lidocaine topical system) 5